中慧生物
Ab&B Bio-Tech

Ab&B Bio-Tech CO., LTD. JS
江蘇中慧元通生物科技股份有限公司

(A joint stock company established in the People's Republic of China with limited liability)

(Stock Code: 2627)

INSIDE INFORMATION
(1) FURTHER DELAY IN PUBLICATION OF ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025 AND DISPATCH OF THE 2025 ANNUAL REPORT;
(2) DELAY IN PUBLICATION OF THE INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026 AND DISPATCH OF THE 2026 INTERIM REPORT;
(3) FURTHER POSTPONEMENT OF BOARD MEETINGS; AND
(4) CONTINUED SUSPENSION OF TRADING

This announcement is made by Ab&B Bio-Tech CO., LTD. JS (the "**Company**", together with its subsidiary, the "**Group**") pursuant to Rules 13.09(2)(a), 13.46(2), 13.48(1), 13.49(1) and 13.49(6) of the Rules (the "**Listing Rules**") Governing the Listing of the Securities on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

References are made to the Company's announcements dated April 1, 14, 24 and 29, 2026, May 27, 2026, June 5, and 30, 2026, in relation to, among other things, (i) the delay in publication of the annual results of the Company for the year ended December 31, 2025 (the "**2025 Annual Results**") and the postponement of the meeting of the board (the "**Board**") of directors (the "**Director(s)**") of the Company; (ii) the suspension of trading; (iii) the change of auditor; (iv) the resumption guidance for the resumption of trading in the shares of the Company; (v) the appointment of independent investigator and independent internal control consultant; and (vi) the quarterly update on resumption process and postponement of the 2025 annual general meeting, (collectively the "**Announcements**"). Unless otherwise defined or the context otherwise requires, capitalized terms in this announcement shall have the same meanings as those defined in the Announcements.

FURTHER DELAY IN PUBLICATION OF ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025 AND DISPATCH OF THE 2025 ANNUAL REPORT

The Board would like to inform the Shareholders and its potential investors of the Company that, the publication of the 2025 Annual Results and the annual report of the Company for the year ended December 31, 2025 (the "**2025 Annual Report**") will be further delayed. As disclosed in the announcements of the Company dated April 14 and 24, 2026 and May 27, 2026, respectively, following the resignation of Deloitte Touche Tohmatsu, the Company appointed CLA Prism Hong Kong Limited (formerly known as Prism Hong Kong Limited) ("**Prism**") as its auditor on May 27, 2026 to conduct the audit of the 2025 Annual Results. As at the date of this announcement, such audit work is still ongoing.

As additional time is required for the Company to fulfill its outstanding obligations under the Resumption Guidance, including the completion of the independent investigation and the independent internal control review, as well as for the Company and Prism to complete the remaining financial reporting and audit procedures in respect of the 2025 Annual Results, it is expected that there will be a further delay in the publication of the 2025 Annual Results and the dispatch of the 2025 Annual Report. The Company will publish further announcement(s) in due course to inform the Shareholders and potential investors of the expected date of publication of the 2025 Annual Results and the expected date of dispatch of the 2025 Annual Report as and when appropriate.

DELAY IN PUBLICATION OF THE INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026 AND DISPATCH OF THE 2026 INTERIM REPORT

Pursuant to Rules 13.49(6) and 13.48(1) of the Listing Rules, the Company is required to (i) publish an announcement for the interim results of the Company for the six months ended June 30, 2026 (the "**2026 Interim Results**") on a date not later than two months after the end of the first six months of each financial year of the Company, namely, on or before August 31, 2026, and (ii) send the interim report of the Group for the six months ended June 30, 2026 (the "**2026 Interim Report**") to its shareholders not later than three months after the end of that period of six months, namely, on or before September 30, 2026.

As at the date of this announcement, as the Company has not yet published the 2025 Annual Results, and the 2026 Interim Results will contain certain financial information from the 2025 Annual Results, the Company expects that the publication of the 2026 Interim Results and the dispatch of the 2026 Interim Report will be delayed. It is expected that the 2026 Interim Results will be published after the publication of the 2025 Annual Results. The Company will publish further announcement(s) in due course to inform the Shareholders and potential investors of the expected date of publication of the 2026 Interim Results, the expected date of the dispatch of the 2026 Interim Report and any other updates as and when appropriate.

The Board acknowledges the delay in publication of the 2026 Interim Results and dispatch of the 2026 Interim Report constitutes non-compliance of Rules 13.49(6) and 13.48(1) of the Listing Rules.

FURTHER POSTPONEMENT OF BOARD MEETINGS

In light of the further delay in the publication of the 2025 Annual Results, the Board meeting for considering and approving, among other matters, the 2025 Annual Results will be further postponed. The Board is currently unable to determine the dates for the Board meeting for considering and approving, among other matters, the 2025 Annual Results and the 2026 Interim Results. Further announcement(s) will be made by the Company to inform the Shareholders of the date(s) of the relevant board meetings as and when appropriate.

CONTINUED SUSPENSION OF TRADING

Trading in the H Shares of the Company on The Stock Exchange of Hong Kong Limited has been suspended with effect from 9:00 a.m. on Wednesday, April 1, 2026 and will remain suspended until further notice.

Further announcement(s) will be made by the Company to keep the Shareholders and potential investors informed of any material development in this regard as and when appropriate.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
Ab&B Bio-Tech CO., LTD. JS
Mr. AN Youcai
Executive Director, chairman of our Board and general manager

Hong Kong, August 31, 2026

As at the date of this announcement, the Board comprises: (i) Mr. AN Youcai, Ms. LI Runxiang and Mr. HE Yiming as executive Directors; (ii) Mr. YU Jianlin and Mr. DU Mu as non-executive Directors; and (iii) Mr. LI Xiangming, Mr. LI Jianjun, Mr. CHEN Chengbei and Ms. LUI Mei Ka as independent non-executive Directors.